I noticed the little 7 they added onto the 2026 date, to my dismay. I remember when it was the Summer of 2025 being targeted (see bulletin 1).
As Silverchair noted, they make a strange comparison to failed biotech stocks, I guess in an attempt to justify their overly conservative approach. If the prospects in vitiligo and photocosmetics are as exciting as the company makes them out to be, then this approach (considering the strong cash balance and steady earnings - very different to the peer companies they used in the slide deck) is to the detriment of enhancing shareholder value. It is very easy for them to turn the share price around, the ball is in their court.
CUV Price at posting:
$9.44 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)